Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40

Goldman Sachs analyst Salveen Richter has reaffirmed a Buy rating on Denali Therapeutics (NASDAQ: DNLI) and increased the price target from $35 to $40. This adjustment reflects a positive outlook for the company's performance.